Sign up to save your podcasts
Or
Share TB-006- a new treatment for Alzheimer's
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
TB-006- a new treatment for Alzheimer's
What if Alzheimer’s and Parkinson’s weren’t just protein problems—but inflammatory ones?
In this episode of The Recharge Biomedical Podcast, Dr. Edward Park sits down with Dr. William Gael to discuss TB-006, a first-in-class humanized antibody targeting Galectin-3, a key driver of chronic brain inflammation.
Unlike traditional Alzheimer’s drugs that focus on amyloid plaques and often fail, TB-006 works by resetting the brain’s immune system. By binding Galectin-3, the drug reduces microglial overactivation, toxic tangles, and neuroinflammation—allowing cognitive and motor function to improve.
Dr. Gael shares compelling real-world outcomes, including his own mother’s rapid cognitive and motor improvements within days of treatment. They also explore TB-006’s broader applications in Parkinson’s disease, Lewy Body dementia, and systemic inflammatory conditions.
Listeners will learn how the drug works, who may benefit, why genetics matter, and how patients can access TB-006 today through the FDA’s Expanded Access (Compassionate Use) program.
Dr. Edward Park and Dr. William Gael discuss TB-006, a breakthrough anti-inflammatory antibody targeting Galectin-3 for Alzheimer’s, Parkinson’s, and neurodegenerative disease treatment.
Dr. William Gael, MD, is a physician-scientist focused on neurodegenerative disease and inflammatory pathways. He has been closely involved in the development and clinical application of TB-006 and is a leading voice in re-framing Alzheimer’s and Parkinson’s as immune-driven diseases.
Connect with Dr. Ed Park
Linkedin: https://www.linkedin.com/in/dredpark/
Instagram: https://www.instagram.com/dredpark/?hl=en
Website: www.rechargebiomedical.com
Recharge Biomedical | Substack
PODCAST
Thank you for listening.
Please subscribe and share.
This podcast is produced by DrTalks.com https://drtalks.com/podcast-service/
View all episodes
By Ed Park, MD, MPHWhat if Alzheimer’s and Parkinson’s weren’t just protein problems—but inflammatory ones?
In this episode of The Recharge Biomedical Podcast, Dr. Edward Park sits down with Dr. William Gael to discuss TB-006, a first-in-class humanized antibody targeting Galectin-3, a key driver of chronic brain inflammation.
Unlike traditional Alzheimer’s drugs that focus on amyloid plaques and often fail, TB-006 works by resetting the brain’s immune system. By binding Galectin-3, the drug reduces microglial overactivation, toxic tangles, and neuroinflammation—allowing cognitive and motor function to improve.
Dr. Gael shares compelling real-world outcomes, including his own mother’s rapid cognitive and motor improvements within days of treatment. They also explore TB-006’s broader applications in Parkinson’s disease, Lewy Body dementia, and systemic inflammatory conditions.
Listeners will learn how the drug works, who may benefit, why genetics matter, and how patients can access TB-006 today through the FDA’s Expanded Access (Compassionate Use) program.
Dr. Edward Park and Dr. William Gael discuss TB-006, a breakthrough anti-inflammatory antibody targeting Galectin-3 for Alzheimer’s, Parkinson’s, and neurodegenerative disease treatment.
Dr. William Gael, MD, is a physician-scientist focused on neurodegenerative disease and inflammatory pathways. He has been closely involved in the development and clinical application of TB-006 and is a leading voice in re-framing Alzheimer’s and Parkinson’s as immune-driven diseases.
Connect with Dr. Ed Park
Linkedin: https://www.linkedin.com/in/dredpark/
Instagram: https://www.instagram.com/dredpark/?hl=en
Website: www.rechargebiomedical.com
Recharge Biomedical | Substack
PODCAST
Thank you for listening.
Please subscribe and share.
This podcast is produced by DrTalks.com https://drtalks.com/podcast-service/